(S)-3-Hydroxybutyric acid
This product is not available for sale in your country. Please feel free to contact the help desk if you have any questions.
Specifications
| CAS No | 6168-83-8 |
| MW | 104.1 |
| Country Availability | DK, EE, FI, IS, LT, LV, NO, SE |
| Data Sheet Link | https://www.adipogen.com/productmanagement/resource/download/type/sheet/id/10793 |
| Description | (S)-3-Hydroxybutyric acid |
| Supplier | Adipogen Life Sciences |
| Notes | Chemical. CAS: 6168-83-8. Formula: C4H8O3. MW: 104.1. Physiologically insignificant stereoisomer of (R)-3-Hydroxybutyric acid, a key metabolite of the ketolytic pathway. Anticonvulsant. Endogenous inhibitor of histone deacetylases (HDACs) 1, 3 and 4. Ligand of free fatty acid receptor 3 (FFAR3; GPR41) and hydroxycarboxylic acid receptor 2 (HCAR2; GPR109B). NLRP3 inflammasome inhibitor. Prevents K+-efflux and reduces ASC oligomerization and speck formation. |
| Molecular Formula | C4H8O3 |
| Alias Names | (S)-beta-Hydroxybutyric acid; L-(+)-3-Hydroxybutyric acid; L-(+)-BHB |
| Protocol | Optical Rotation: [alpha]20/D c=6 in H2O: 25°±1.0° |
| Purity | >98% (TLC) |
| References | Effects of beta-hydroxy butyric acid on insulin binding to its receptor and on autophosphorylation of the receptor: H. Ohtusaka, et al.; Endocrinol. Jpn. 37, 915 (1990) | Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo: J.M. Rho, et al.; Epilepsia 43, 358 (2002) | The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment: M. Vanelli, et al.; Diabetes Nutr. Metab. 16, 312 (2003) | Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis: S.L. Wootton-Gorges, et al.; AJNR 26, 1286 (2005) | beta-Hydroxybutyrate activates the NF-kappaB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes: X. Shi, et al.; Cell. Physiol. Biochem. 33, 920 (2014) | beta-hydroxybutyrate: Much more than a metabolite: J. C. Newman & E. Verdin; Diab. Res. Clin. Pract. 106, 173 (2014) (Review) | BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-kappaB activation: S.P. Fu, et al.; Med. Inflamm. 2014, ID983401 (2014) | Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms: S.P. Fu, et al.; J. Neuroinflamm. 12, ID9 (2015) | The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease: Y.H. Youm, et al.; Nat. Med. 21, 263 (2015) | Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015) | Inflammasome inhibition: putting out the fire: M.G. Netea & L.A. Joosten; Cell Metab. 21, 513 (2015) | Inflammasome: starving inflammation: E. Kugleberg; Nat. Rev. Immunol. 15, 199 (2015) (Review) | The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015) (Review) |
| Solubility | Soluble in water, 100% ethanol or methanol. |
| Source / Host | synthetic |
| Storage | -20°C |
| Technical Specifications | Physiologically insignificant stereoisomer of (R)-3-Hydroxybutyric acid, a key metabolite of the ketolytic pathway. Anticonvulsant. Endogenous inhibitor of histone deacetylases (HDACs) 1, 3 and 4. Ligand of free fatty acid receptor 3 (FFAR3; GPR41) and hydroxycarboxylic acid receptor 2 (HCAR2; GPR109B). NLRP3 inflammasome inhibitor. Prevents K+-efflux and reduces ASC oligomerization and speck formation. |
Shipping info
The delivery time for this item is approximately 5-8 business days. If other deviations occur, this will be noted on the order confirmation or communicated via email. Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.
Source/Host:
syntheticProduct insert:
Datasheet